Good morning, everyone, and how are you today? We are doing just fine, thank you, despite the cloudy skies looming over the Pharmalot campus. After all, the birds are still chirping and a cool breeze is wafting by. Moreover, this marks the middle of the week, which means we have managed to survive this far. And this calls for celebration, yes? So please join us as we hoist another cup of delicious stimulation. Remember, no prescription is required. Meanwhile, here are a few items of interest. Have a grand day and drop us a line if you hear something saucy. …
Pfizer (PFE) and BioNTech (BNTX) reported that their Covid-19 vaccine prevented symptomatic disease and was well-tolerated in a Phase 3 study of adolescents ages 12 to 15, STAT reports. The companies say they will submit the data to the Food and Drug Administration as an amendment to the vaccine’s emergency use authorization, and will also submit the results to other regulators around the world. The companies hope it will be possible to begin vaccinating adolescents in this age group before the beginning of the next school year.
Meanwhile, Pfizer and BioNTech plan to begin soon testing a freeze-dried version of their Covid-19 vaccine, which if proven to work safely could ease storage and handling of the shots in rural U.S. areas and low-income countries, The Wall Street Journal tells us. In April, Pfizer is set to start a clinical trial evaluating a so-called lyophilized formulation in adults 18 to 55 years old in the U.S. The 1,100-subject study would last about two months, with researchers seeking to determine this version is as safe and effective as the shot authorized by regulators.
About the Author Reprints
